Life Sciences

  • February 05, 2024

    Spinal Implant Maker Previews Ch. 11 Sale And Wind Down

    Bankrupt biotechnology developer InVivo Therapeutics Corp. will auction its assets and hopefully propose a Chapter 11 wind down plan in April, attorneys told a Delaware bankruptcy court Monday at a first day hearing.

  • February 05, 2024

    Biotech Co. NanoString Hits Ch. 11 In Del. With $325M Debt

    Life sciences company NanoString Technologies Inc. and three affiliates filed for Chapter 11 protection in Delaware bankruptcy court with $325 million in debt and $275 million in assets, months after a jury found it infringed several gene-technology patents.

  • February 05, 2024

    Novo Holdings Buying Biopharma Co. Catalent In $16.5B Deal

    Novo Holdings, the controlling shareholder in Novo Nordisk Foundation, said Monday it has agreed to acquire Catalent in an all-cash transaction that values the pharmaceutical company at $16.5 billion, including debt, about five months after Catalent struck a deal with activist investor Elliott Investment Management to conduct a strategic review. 

  • February 02, 2024

    Eli Lilly, Sanofi Beat Antitrust Suit Alleging Insulin Conspiracy

    A New York federal judge on Thursday tossed an antitrust suit alleging major drug manufacturers conspired to retract insulin discounts to boost profits, saying the companies developed their drug policies separately and not in conjunction with one another.

  • February 02, 2024

    McKinsey's $78M Opioid Deal With Health Plans Hits Snag

    A California federal judge considering a $78 million deal between third-party payors and McKinsey & Co. in multidistrict litigation over the consulting firm's marketing advice to opioid makers held off on preliminarily approving the deal Friday, instead setting a new hearing date after some plaintiffs' attorneys raised issues with aspects of the deal.

  • February 02, 2024

    USPTO Slams Lundbeck's PTSD Drug Patent Term Suit

    The U.S. Patent and Trademark Office is going for an early win in Virginia federal court where Danish drugmaker H. Lundbeck A/S is seeking to extend the life of a patent for a PTSD drug by three months, calling the case straightforward.

  • February 02, 2024

    4th Circ. Vacates Va. Doctor's Conviction In Pill Mill Scheme

    The Fourth Circuit on Friday called for a new trial of a doctor who was sentenced to 40 years in prison over his opioid-prescription practices, finding that the jury was erroneously instructed during his trial.

  • February 02, 2024

    Harvard Prof. Slams Study Showing IQ Gains From Fluoride

    A Harvard epidemiologist testifying Friday in a high-stakes bench trial over fluoridated water's risks criticized a study cited by the government that found fluoride exposure increases IQ by 24 points, saying the results "don't make sense," are "beyond the imagination" and must be based on erroneous data.

  • February 02, 2024

    ABA Chides 5th Circ. At High Court Over Mifepristone Ruling

    The American Bar Association on Friday urged the U.S. Supreme Court to undo a Fifth Circuit opinion affirming limits on access to the abortion medication mifepristone, saying it doesn't typically weigh in on such cases, but asserting the appeals court wrongly "second-guessed" the Food and Drug Administration.

  • February 02, 2024

    Judge Tosses Involuntary Releases In Amyris Ch. 11 Plan

    A Delaware bankruptcy judge on Friday struck down biotechnology company Amyris Inc.'s plan to shield executives and others from liability using nonconsensual releases as part of its Chapter 11 plan, finding that Amyris can reorganize without relying on the controversial mechanism.

  • February 02, 2024

    Drugmaker Endo Wants To Extend Opioid Suit Pause

    Endo has asked a New York bankruptcy judge to pause the opioid litigation leveled against it for five more months, asserting that the pharmaceutical company made "wide-ranging progress" in its Chapter 11 case and expects to have a reorganization plan confirmed by March.

  • February 02, 2024

    ACLU Atty On How To Protect Civil Liberties In The AI Era

    Because artificial intelligence and algorithmic systems often operate in the shadows, there's a new need for legislation, regulation and enforcement to ensure the technology doesn't undercut civil liberties by engaging in discrimination in housing, education or employment, according to Cody Venzke, senior policy counsel for the American Civil Liberties Union.

  • February 02, 2024

    Families New To Tylenol MDL Cite Expert To Avoid Dismissal

    A dozen parents and children who allege that prenatal exposure to acetaminophen caused ADHD have urged a federal judge to keep their lawsuits alive, contending that they aren't bound by an earlier ruling that barred every expert witness set to testify for plaintiffs in similar cases.

  • February 02, 2024

    Latham Led Firms In January IPOs As New Listings Pick Up

    Latham & Watkins LLP assumed work on more initial public offerings than any other law firm in January, steering five IPOs for companies and underwriters during a month that saw a rise in new listings that could portend additional momentum beyond February.

  • February 02, 2024

    Ascension Says Medical Queries Don't Breach Genetic Privacy

    Questions about family medical history raised during a hospital job interview don't implicate an Illinois genetic privacy law, healthcare giant Ascension Health has told a Missouri federal court.

  • February 02, 2024

    Pennsylvania AG's Clout In Opioid Deal Likely Has Wide Reach

    A Pennsylvania court's ruling that the attorney general had the power to overrule local district attorneys' objections to a big opioid settlement could affect the prosecutors' power dynamic beyond the painkiller litigation, overshadowing other areas where they could share jurisdiction or clash over politically sensitive issues, attorneys told Law360.

  • February 02, 2024

    McCarter & English To Face Revised Biotech Malpractice Suit

    A New Jersey state judge on Friday permitted a biopharmaceutical company to amend its malpractice suit against McCarter & English LLP to add new claims and avenues to collect damages, finding the changes were "sufficiently pled" and would not be prejudicial to the firm.

  • February 02, 2024

    DLA Piper Hires McDermott's FDA Practice Leader In DC

    DLA Piper LLP has hired the leader of McDermott Will & Emery's U.S. Food and Drug Administration-focused practice as the new co-chair of their own FDA practice, according to a Thursday announcement.

  • February 02, 2024

    UK Regulator Examining Thermo Fisher's $3.1B Olink Buy

    The U.K.'s Competition and Markets Authority said Friday that it is looking into American biotechnology company Thermo Fisher Scientific's planned $3.1 billion purchase of Swedish biotech business Olink to determine whether it will result in reduced competition.

  • February 02, 2024

    2 Biotech Firms Tap Thawing IPO Market To Raise $239M Total

    Shares of drug developers Fractyl Health Inc. and Alto Neuroscience Inc. began trading with mixed results on Friday after the life sciences startups raised nearly $239 million combined in initial public offerings, guided by three law firms.

  • February 01, 2024

    Ex-FDA Leaders Urge High Court To Nix Mifepristone Ruling

    Seven former commissioners and acting commissioners of the U.S. Food and Drug Administration told the U.S. Supreme Court on Thursday that a Fifth Circuit decision reinstating some restrictions on mifepristone, a drug used to end early pregnancies and manage miscarriages, threatens the nation's drug approval process.

  • February 01, 2024

    Harvard Professor Testifies Fluoride Is 'Definitely' Neurotoxic

    A Harvard epidemiologist testified in a high-stakes bench trial over environmental groups' efforts to get the U.S. Environmental Protection Agency to ban fluoride in 200 million Americans' drinking water that there is "definitely a causal relationship" between fluoride exposure and neurotoxicity, even at low exposure levels.

  • February 01, 2024

    Stimwave Trustee Seeks Stay Of Perryman Actions In Ch. 11

    Stimwave Technologies' liquidating trustee asked a Delaware judge to pause almost all the adversary suits by the company's ex-CEO and her family until the court can mull its objections to the claims.

  • February 01, 2024

    Pharma Hikma Reaches $150M Opioid Settlement With States

    Hikma Pharmaceuticals and several attorneys general announced a $150 million agreement in principle on Thursday resolving cases brought by a group of states and localities alleging the company fueled the opioid crisis by failing to report suspicious opioid orders from potentially illegal distributors.

  • February 01, 2024

    Assa Abloy Nabs PTAB Win Against Biometric Security Patent

    The Patent Trial and Appeal Board has invalidated all claims in a CPC Patent Technologies Pty Ltd. biometric security patent that was attacked in a pair of challenges by Assa Abloy AB.

Expert Analysis

  • White House Activity Is A Band-Aid For Regulating AI In Health

    Author Photo

    In the medium term, recent White House actions will have a greater impact on AI in the health care industry than Congress' sluggish efforts to regulate it, but ultimately legislation of AI's development and use in the health space will fall to Congress, say Wendell Bartnick and Vanessa Perumal at Reed Smith.

  • Understanding Discovery Obligations In Era Of Generative AI

    Excerpt from Practical Guidance
    Author Photo

    Attorneys and businesses must adapt to the unique discovery challenges presented by generative artificial intelligence, such as chatbot content and prompts, while upholding the principles of fairness, transparency and compliance with legal obligations in federal civil litigation, say attorneys at King & Spalding.

  • Kochava Ruling May Hint At Next Privacy Class Action Wave

    Author Photo

    The Southern District of California's recent ruling in Greenley v. Kochava and increasing complaints alleging that a consumer website is an illegal “pen register” due to the use of third-party marketing software tools foreshadow a new theory of liability for plaintiffs in privacy litigation, say attorneys at Crowell & Moring.

  • Forecasting The Impact Of High Court Debit Card Rule Case

    Author Photo

    John Delionado and Aidan Gross at Hunton consider how the U.S. Supreme Court's forthcoming ruling in a retailer's suit challenging a Federal Reserve rule on debit card swipe fees could affect agency regulations both new and old, as well as the businesses that might seek to challenge them.

  • Series

    ESG Around The World: Mexico

    Author Photo

    ESG has yet to become part of the DNA of the Mexican business model, but huge strides are being made in that direction, as more stakeholders demand that companies adopt, at the least, a modicum of sustainability commitments and demonstrate how they will meet them, says Carlos Escoto at Galicia Abogados.

  • Opinion

    FDA And Companies Must Move Quickly On Drug Recalls

    Author Photo

    When a drug doesn't work as promised — whether it causes harm, like eyedrops recalled last month by the U.S. Food and Drug Administration, or is merely useless, like a widely used decongestant ingredient recently acknowledged by the agency to be ineffective — the public must be notified in a timely manner, says Vineet Dubey at Custodio & Dubey.

  • The Case For Post-Bar Clerk Training Programs At Law Firms

    Author Photo

    In today's competitive legal hiring market, an intentionally designed training program for law school graduates awaiting bar admission can be an effective way of creating a pipeline of qualified candidates, says Brent Daub at Gilson Daub.

  • Opinion

    A Telecom Attorney's Defense Of The Chevron Doctrine

    Author Photo

    The Chevron doctrine, which requires judicial deference to federal regulators, is under attack in two U.S. Supreme Court cases — and while most telecom attorneys likely agree that the Federal Communications Commission is guilty of overrelying on it, the problem is not the doctrine itself, says Carl Northrop at Telecommunications Law Professionals.

  • What's At Stake In Bystolic 'Side Deals' Litigation

    Author Photo

    In re: Bystolic Antitrust Litigation, which has oral argument set for next month, will likely shed light on how the U.S. Court of Appeals for the Second Circuit views side deals, and could create a circuit split in pleading standards for reverse payment cases, say attorneys at Axinn.

  • 2 HHS Warnings Highlight Anti-Kickback Risks For Physicians

    Author Photo

    Two recent advisory opinions issued by the U.S. Department of Health and Human Services' Office of Inspector General involve different scenarios and rationales, but together they illustrate the OIG's focus on and disapproval of contractual joint ventures and other revenue-maximizing physician arrangements, say Robert Threlkeld and Elliott Coward at Morris Manning.

  • Attorneys Have An Ethical Duty To Protect The Judiciary

    Author Photo

    The tenor of public disagreement and debate has become increasingly hostile against judges, and though the legislative branch is trying to ameliorate this safety gap, lawyers have a moral imperative and professional requirement to stand with judges in defusing attacks against them and their rulings, says Deborah Winokur at Cozen O'Connor.

  • Cross-Market Implications In FTC's Anesthesia Complaint

    Author Photo

    The Federal Trade Commission's recent complaint against a private equity firm's acquisition of anesthesiology practices highlights the controversial issue of cross-market harm in health care provider mergers, and could provide important insights into how a court may view such theories of harm, say Christopher Lau and Dina Older Aguilar at Cornerstone Research.

  • FTC Orange Book Move Signals New Pharma Patent Scrutiny

    Author Photo

    The Federal Trade Commission's recent dispute against improper listing of drug patents in the U.S. Food and Drug Administration's Orange Book indicates heightened surveillance of the pharmaceutical industry, particularly where competition-related consequences of patent or regulatory processes are concerned, say attorneys at Fenwick.

  • AI Can Help Lawyers Overcome The Programming Barrier

    Author Photo

    Legal professionals without programming expertise can use generative artificial intelligence to harness the power of automation and other technology solutions to streamline their work, without the steep learning curve traditionally associated with coding, says George Zalepa at Greenberg Traurig.

  • How Legal Teams Can Prep For Life Sciences' Tech Revolution

    Author Photo

    The life sciences and health care industries are uniquely positioned to take advantage of new efficiencies created by cloud computing and generative artificial intelligence, but the sensitivity of their data also demands careful navigation of an expanding legislative and regulatory landscape, say Kristi Gedid, Zack Laplante and Lisa LaMotta at Ernst & Young.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.
Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!